AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes
AbbVie is conducting a trial to evaluate the safety and efficacy of ABBV-932 in adults with depressive episodes linked to bipolar I or II disorder.
Phase III
Neurology / Bipolar Disorder
Status
Active
Sponsor
AbbVie
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the ABBV-932 trial represents a significant opportunity for AbbVie to address a critical gap in treatment options for bipolar disorder, a condition affecting a substantial portion of the adult population. Success in this trial could enhance AbbVie's competitive positioning and market share in the neurology therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment progress, interim results, and any safety signals reported during the trial.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.